Clinical Trial

An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L

Study acronym: EUMELEIA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the efficacy of the alternating D-PAD/D-CVD induction regimen followed by D-CVD consolidation regimen and maintenance with daratumumab monotherapy, in terms of PFS, in the first-line setting of pPCL.
Trial Details
NCT Number NCT06636552
Lead Sponsor Hellenic Society of Hematology
Conditions Primary Plasma Cell Leukemia
Enrollment 43 participants
Start Date 2021-11-19
Primary Completion 2029-01-05 (estimated)
Study Completion 2029-01-05 (estimated)
Updated on ClinicalTrials.gov 2024-10-10